Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment

File Description SizeFormat 
Misra_et_al-2018-Diabetic_Medicine.pdfPublished version247.45 kBAdobe PDFDownload
Title: Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
Author(s): Misra, S
Vedovato, N
Cliff, E
De franco, E
Hattersley, A
Ashcroft, F
Oliver, N
Item Type: Journal Article
Abstract: Background Permanent neonatal diabetes caused by mutations in the KCNJ11 gene may be managed with high‐dose sulfonylureas. Complete transfer to sulfonylureas is not successful in all cases and can result in insulin monotherapy. In such cases, the outcomes of combining sulfonylureas with insulin have not been fully explored. We present the case of a woman with diabetes due to a KCNJ11 mutation, in whom combination therapy led to clinically meaningful improvements. Case A 22‐year‐old woman was found to have a KCNJ11 mutation (G334V) following diagnosis with diabetes at 3 weeks. She was treated with insulin‐pump therapy, had hypoglycaemia unawareness and suboptimal glycaemic control. We assessed the in vitro response of the mutant channel to tolbutamide in Xenopus oocytes and undertook sulfonylurea dose‐titration with C‐peptide assessment and continuous glucose monitoring. In vitro studies predicted the G334V mutation would be sensitive to sulfonylurea therapy [91 ± 2% block (n = 6) with 0.5 mM tolbutamide]. C‐peptide increased following a glibenclamide test dose (from 5 to 410 pmol/l). Glibenclamide dose‐titration was undertaken: a lower glibenclamide dose did not reduce blood glucose levels, but at 1.2 mg/kg/day insulin delivery was reduced to 0.1 units/h. However, when insulin was stopped, hyperglycaemia ensued. Glibenclamide was further increased (2 mg/kg/day), but once‐daily long‐acting insulin was still required to maintain glycaemia. This resulted in improved HbA1c of 52 mmol/mol (6.9%), restoration of hypoglycaemia awareness and reduced glycaemic variability. Conclusion In people with KCNJ11 mutations causing permanent neonatal diabetes, and where complete transfer is not possible, consideration should be given to dual insulin and sulfonylurea therapy.
Publication Date: 1-Sep-2018
Date of Acceptance: 30-Apr-2018
URI: http://hdl.handle.net/10044/1/60719
DOI: https://dx.doi.org/10.1111/dme.13758
ISSN: 0742-3071
Publisher: Wiley
Start Page: 1291
End Page: 1296
Journal / Book Title: Diabetic Medicine
Volume: 35
Issue: 9
Copyright Statement: © 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
MUTATIONS
KCNJ11
KIR6.2
THERAPY
1103 Clinical Sciences
Endocrinology & Metabolism
Publication Status: Published
Online Publication Date: 2018-06-13
Appears in Collections:Department of Medicine
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons